Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs

Jose Jg Marin; Rocio Ir Macias

doi:10.1080/13543784.2021.1916912

Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs

Expert Opin Investig Drugs. 2021 Jul;30(7):675-679. doi: 10.1080/13543784.2021.1916912. Epub 2021 May 2.

Authors

Jose Jg Marin¹, Rocio Ir Macias¹

Affiliation

¹ Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, CIBERehd, Salamanca, Spain.

PMID: 33934687
DOI: 10.1080/13543784.2021.1916912

No abstract available

Keywords: Biliary tract cancer; FGFR; cholangiocarcinoma; drug resistance; immunotherapy; liver cancer; pharmacoresistance; targeted therapy; tumor heterogeneity.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology*
Bile Duct Neoplasms / drug therapy*
Bile Duct Neoplasms / pathology
Cholangiocarcinoma / drug therapy*
Cholangiocarcinoma / pathology
Drug Development
Drug Resistance, Neoplasm
Drugs, Investigational / pharmacology
Humans

Substances

Antineoplastic Agents
Drugs, Investigational